Clinical Trials Directory

Trials / Unknown

UnknownNCT03903393

Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia

Status
Unknown
Phase
Study type
Observational
Enrollment
260 (estimated)
Sponsor
First Affiliated Hospital of Harbin Medical University · Academic / Other
Sex
Female
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

To identify lncRNAs differentially expressed at early stages of gestation in the serum of pregnant women, who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with normal pregnancy .

Detailed description

Preeclampsia (PE) is a pregnancy syndrome characterized by hypertension and proteinuria, and a leading cause of maternal and fetal morbidity and mortality, with poorly defined pathophysiological mechanisms remain. Circulating lncRNAs are long, noncoding RNA molecules, which negatively regulate gene expression, and considered as promising biomarkers for PE. The objective of the study is to evaluate circulating lncRNA signatures in women with PE compared to healthy women, and in women sub-grouped per PE severity. This study assessed lncRNA expression profile in the serum at early stages of gestation of women who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with uncomplicated pregnancies. Circulating lncRNA was extracted from maternal serum. This study also assess lncRNA expression profile in the placenta tissues of PE patients and healthy pregnant women.

Conditions

Timeline

Start date
2019-03-31
Primary completion
2021-03-01
Completion
2021-03-01
First posted
2019-04-04
Last updated
2019-12-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03903393. Inclusion in this directory is not an endorsement.

Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia (NCT03903393) · Clinical Trials Directory